Abstract
Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 140-153 |
| Number of pages | 14 |
| Journal | Cardiology in the Young |
| Volume | 25 |
| Issue number | S2 |
| DOIs | |
| State | Published - Sep 17 2015 |
Fingerprint
Keywords
- Cardiomyopathy
- heart failure
- paediatrics
- patient registry
- Pediatric Cardiomyopathy Registry
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pediatrics, Perinatology, and Child Health
Cite this
Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group. / Wilkinson, James D.; Westphal, Joslyn A.; Bansal, Neha; Czachor, Jason D.; Razoky, Hiedy; Lipshultz, Steven E.
In: Cardiology in the Young, Vol. 25, No. S2, 17.09.2015, p. 140-153.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group
AU - Wilkinson, James D.
AU - Westphal, Joslyn A.
AU - Bansal, Neha
AU - Czachor, Jason D.
AU - Razoky, Hiedy
AU - Lipshultz, Steven E
PY - 2015/9/17
Y1 - 2015/9/17
N2 - Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.
AB - Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.
KW - Cardiomyopathy
KW - heart failure
KW - paediatrics
KW - patient registry
KW - Pediatric Cardiomyopathy Registry
UR - http://www.scopus.com/inward/record.url?scp=84941881700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941881700&partnerID=8YFLogxK
U2 - 10.1017/S1047951115000943
DO - 10.1017/S1047951115000943
M3 - Article
VL - 25
SP - 140
EP - 153
JO - Cardiology in the Young
JF - Cardiology in the Young
SN - 1047-9511
IS - S2
ER -